Compare, Analyse RANBAXY LAB (500359 | ) with SUN PHARMA (524715 | SUNPHARMA~EQ)
X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2016 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
 
  
Compare another company

  
  

RANBAXY LAB vs SUN PHARMA - Comparison Results

  
  

RANBAXY LAB 
  Change

Ranbaxy is India's top pharmaceutical company, manufacturing and marketing branded generic pharmaceuticals products and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on US and European markets has helped it build deep product pipelines... More


SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Stock Price Chart: ranbaxy lab Vs. sun pharma
Loading...
 
 
DO YOU LIKE THESE REPORTS? TELL US!
 Current Valuations
    RANBAXY LAB SUN PHARMA RANBAXY LAB/  
SUN PHARMA  
P/E (TTM) x -83.3 37.5 - View Chart
P/BV x 11.1 6.7 165.2% View Chart
Dividend Yield % 0.0 0.4 -  
 
 Financials
 RANBAXY LAB   SUN PHARMA
  EQUITY SHARE DATA
    RANBAXY LAB SUN PHARMA RANBAXY LAB/ 5-Yr Chart
    Mar-14 Mar-15 SUN PHARMA Click to enlarge
High Rs5251,074 48.9%   
Low Rs254570 44.5%   
Sales per share (Unadj.) Rs313.4132.5 236.6%  
Earnings per share (Unadj.) Rs-25.621.9 -117.0%  
Cash flow per share (Unadj.) Rs-14.427.7 -52.0%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs78.0123.7 63.1%  
Shares outstanding (eoy) m423.322,071.16 20.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.26.2 20.0%   
Avg P/E ratio x-15.237.5 -40.5%  
P/CF ratio (eoy) x-27.129.7 -91.1%  
Price / Book Value ratio x5.06.6 75.1%  
Dividend payout %013.7 0.0%   
Avg Mkt Cap Rs m164,8831,703,011 9.7%   
No. of employees `00015.330.0 51.0%   
Total wages/salary Rs m25,77544,299 58.2%   
Avg. sales/employee Rs Th8,672.29,144.5 94.8%   
Avg. wages/employee Rs Th1,684.61,476.6 114.1%   
Avg. net profit/employee Rs Th-709.31,513.1 -46.9%   
 
  INCOME DATA
Net Sales Rs m132,685274,334 48.4%  
Other income Rs m1,8283,403 53.7%   
Total revenues Rs m134,513277,737 48.4%   
Gross profit Rs m9,73280,741 12.1%  
Depreciation Rs m4,76211,947 39.9%   
Interest Rs m5,5735,790 96.2%   
Profit before tax Rs m1,22666,407 1.8%   
Minority Interest Rs m20-9,363 -0.2%   
Prior Period Items Rs m-140-126 111.8%   
Extraordinary Inc (Exp) Rs m-8,643-2,378 363.5%   
Tax Rs m3,3149,147 36.2%   
Profit after tax Rs m-10,85245,394 -23.9%  
Gross profit margin %7.329.4 24.9%  
Effective tax rate %270.413.8 1,963.2%   
Net profit margin %-8.216.5 -49.4%  
 
  BALANCE SHEET DATA
Current assets Rs m70,357291,219 24.2%   
Current liabilities Rs m75,760163,530 46.3%   
Net working cap to sales %-4.146.5 -8.7%  
Current ratio x0.91.8 52.1%  
Inventory Days Days7675 100.7%  
Debtors Days Days5771 80.6%  
Net fixed assets Rs m53,839110,201 48.9%   
Share capital Rs m2,1172,071 102.2%   
"Free" reserves Rs m22,130222,763 9.9%   
Net worth Rs m33,031256,232 12.9%   
Long term debt Rs m24,74413,684 180.8%   
Total assets Rs m139,901490,279 28.5%  
Interest coverage x1.212.5 9.8%   
Debt to equity ratio x0.70.1 1,402.7%  
Sales to assets ratio x0.90.6 169.5%   
Return on assets %-3.810.4 -36.2%  
Return on equity %-32.917.7 -185.5%  
Return on capital %-3.422.4 -15.2%  
Exports to sales %27.616.9 163.8%   
Imports to sales %6.94.5 154.7%   
Exports (fob) Rs m36,62246,235 79.2%   
Imports (cif) Rs m9,14812,229 74.8%   
Fx inflow Rs m50,93948,706 104.6%   
Fx outflow Rs m23,50525,564 91.9%   
Net fx Rs m27,43423,142 118.5%   
 
  CASH FLOW
From Operations Rs m-35,62453,219 -66.9%  
From Investments Rs m18,320-26,710 -68.6%  
From Financial Activity Rs m10,162-10,875 -93.4%  
Net Cashflow Rs m-7,14315,635 -45.7%  
 
 Share Holding
Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 63.4 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 11.8 23.0 51.3%  
ADR/GDR % 1.5 0.0 -  
Free float % 15.0 8.3 180.7%  
Shareholders   182,721 133,026 137.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
Compare RANBAXY LAB With: DR. REDDYS LAB | STERLING BIOTECH | JUBILANT LIFE SCIENCES | VENUS REMEDIES | IPCA LABS
Compare RANBAXY LAB With: MYLAN (US) | ACTAVIS (US) | ADCOCK INGRAM (S. Africa) | TEVA PHARMA (Israel)

Related Views on News

Cipla Limited: On a growth drive (Cool Hand Luke)

Mar 21, 2014

Luke Verghese discusses that Cipla's financials are on a roll

Cipla Limited: On a growth drive (Cool Hand Luke)

Mar 21, 2014

Luke Verghese discusses that Cipla's financials are on a roll

More Views on News

Most Popular

Satyajit Das Tells Us What is Really Happening in China(The Daily Reckoning)

Jan 29, 2016

The third and the concluding part of a three-part interview with the famous economic commentator and derivatives expert.

A Little-Known Strategy for Great Returns(The 5 Minute Wrapup)

Jan 30, 2016

The secret behind Warren Buffett's outperformance not many are aware of.

How I Manage Risk in Trading(Daily Profit Hunter)

Feb 3, 2016

Apurva Sheth shows the portfolio tracker built specially to manage risk in trading

Is Consumption Boom Over In India?(Mutual Fund Corner)

Feb 2, 2016

Mutual funds take a bearish call on the FMCG sector. The sector has started playing out due to a combination of slower growth and expensive valuations.

How to Find a Saint Amongst Sinners?(Mutual Fund Corner)

Feb 1, 2016

Ethical practices help build long lasting relationships, and healthy long-term business relationships are often mutually rewarding. But PersonalFN is of the view that the financial services industry in India seems to have forgotten this.

More

RANBAXY LAB STOCK QUOTE



Apr 1, 2015 (Close)
View Detailed Quote

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

RANBAXY LAB 5-YR ANALYSIS

Detailed Financial Information With Charts

COMPARE RANBAXY LAB WITH

MARKET STATS

  1. Go